GLP-1 microdosing is not an FDA-approved dosing protocol for semaglutide or tirzepatide. Do not create your own microdose by splitting pens, counting clicks, taking injections more often, or converting milligrams into syringe units. The 2026 FDA prescribing information uses fixed doses and gradual increases. For example, Wegovy starts at 0.25 mg once weekly.

The safer approach is to start with the labeled dose and ask the prescribing clinician to hold or slow the titration if side effects occur.

What Does "Microdosing" a GLP-1 Mean?

"Microdosing" is an informal term for using a dose or schedule that differs from the approved instructions. It may refer to:

  • Taking less than the medication's labeled starting dose
  • Staying at a low dose longer than the standard schedule
  • Splitting one weekly dose into multiple smaller injections
  • Using a compounded vial and measuring a very small amount

Only the second option, slower titration under medical supervision, can fit the dosing principles in FDA prescribing information. FDA-approved labels use fixed doses and gradual increases to reduce gastrointestinal side effects.

What Is the Safest Low-Dose Approach?

The safest approach is to use an FDA-approved product exactly as prescribed, stay at each dose long enough to assess how you tolerate it, and increase the dose only when the prescriber confirms that it is appropriate.

Medication FDA-labeled injectable starting schedule What to do if side effects occur
Wegovy (semaglutide) 0.25 mg once weekly for weeks 1 to 4, followed by gradual increases every four weeks The prescribing information allows dosage escalation to be delayed when a dose is not tolerated
Zepbound (tirzepatide) 2.5 mg once weekly for four weeks, then 5 mg once weekly. Later increases are made in 2.5 mg steps after at least four weeks on the current dose Ask the prescriber whether to remain at the current dose or use a lower maintenance dose

Wegovy's labeled adult injectable maintenance doses are generally 1.7 mg or 2.4 mg weekly, depending on the indication and tolerability. Zepbound's labeled adult maintenance doses are 5 mg, 10 mg, or 15 mg weekly. The 2.5 mg Zepbound dose is intended for treatment initiation, not long-term weight management.

Can You Split a Weekly GLP-1 Dose?

Do not split a weekly dose unless the prescribing clinician gives you a specific written plan. Taking smaller injections more often changes the approved schedule and may increase the risk of medication errors or side effects.

FDA-approved injectable semaglutide and Zepbound products use specified strengths and administration schedules. Changing the dose or frequency can lead to excessive drug exposure, especially because semaglutide remains in the body for a prolonged period.

Do not:

  • Count pen clicks to estimate a dose
  • Withdraw medication from a prefilled pen
  • Take part of a dose and save the remainder
  • Inject a weekly dose more than once per week
  • Combine Wegovy, Ozempic, Zepbound, Mounjaro, or another GLP-1 medication unless specifically instructed
  • Convert milligrams into "units" without confirmation from the dispensing pharmacist

What About Compounded Semaglutide or Tirzepatide?

Compounded GLP-1 products require extra caution because concentrations can vary between pharmacies and products. FDA reports describe dosing mistakes caused by confusion between milligrams, milliliters, and syringe "units." Some patients received five to twenty times the intended semaglutide dose, and some required medical attention or hospitalization.

If a clinician has prescribed a compounded product, confirm each of the following with the prescriber or pharmacist before injecting:

  1. The medication name and active ingredient
  2. The concentration, such as milligrams per milliliter
  3. The exact prescribed dose in milligrams
  4. The exact volume to draw into the syringe
  5. The syringe size and measurement markings
  6. How often the dose should be administered

Do not calculate the dose yourself from an online chart. FDA-approved medications are preferred when they meet the patient's medical needs because compounded drugs do not undergo the same FDA premarket review for safety, quality, and effectiveness.

How Can You Reduce Side Effects Without Microdosing?

You can reduce the risk of worsening side effects by contacting the prescribing clinician before increasing the dose if nausea, early fullness, constipation, vomiting, or diarrhea develops. The clinician may decide to:

  • Keep you at the current dose longer
  • Delay the next increase
  • Return to a previously tolerated dose
  • Review other medicines that worsen nausea or affect blood sugar
  • Check for dehydration, gallbladder disease, or another cause of symptoms

Do not increase the dose simply because weight loss has slowed for a few days. GLP-1 medications are titrated over time, and gastrointestinal reactions are often most noticeable during dose increases.

When Should You Seek Urgent Medical Help?

Seek urgent medical care for:

  • Persistent or severe abdominal pain, especially pain that radiates to the back
  • Repeated vomiting or diarrhea that makes it difficult to keep fluids down
  • Fainting, severe weakness, confusion, or signs of dehydration
  • Symptoms of low blood sugar, especially if you also use insulin or a sulfonylurea
  • Facial swelling, difficulty breathing, or other signs of a serious allergic reaction

Severe or persistent abdominal pain can indicate pancreatitis. Prolonged vomiting or diarrhea can cause dehydration and kidney injury. The risk of hypoglycemia is higher when a GLP-1 medication is used with insulin or an insulin-releasing diabetes medicine.

Who Should Not Self-Start or Self-Adjust a GLP-1 Medication?

Speak with a qualified prescriber before treatment if you:

  • Are pregnant or trying to become pregnant
  • Have a personal or family history of medullary thyroid carcinoma
  • Have Multiple Endocrine Neoplasia syndrome type 2
  • Have severe gastroparesis or severe gastrointestinal disease
  • Use insulin or other medicines that can cause hypoglycemia
  • Have a history of pancreatitis, gallbladder disease, or significant kidney problems

Wegovy and Zepbound are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Weight-loss treatment should be discontinued when pregnancy is recognized.

Bottom Line

Use the labeled starting dose and let the prescribing clinician decide whether to hold, delay, or reduce a dose. If side effects are troublesome, ask whether you should remain at the current dose longer. Do not alter a pen, split doses, inject more often, or convert compounded medication into syringe units without direct confirmation from the prescriber or pharmacist.